Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trialTakehito Shukuya, Kazuhisa Takahashi, Tetsuhiko Asao et al.|The Lancet Oncology|2025Cited by 20
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)Tetsuhiko Asao, Kazuhisa Takahashi, Takehito Shukuya et al.|Clinical Lung Cancer|2023Cited by 5
Candidates for intensive local treatment in cIIIA-N2 NSCLC: Impact of mediastinal nodal extent and appearance.Hidehito Horinouchi, Tomohide Tamura, Hidenori Mizugaki et al.|Journal of Clinical Oncology|2014Cited by 0